Literature DB >> 10942031

Neuronal nicotinic acetylcholine receptors: from the gene to the disease.

S Weiland1, D Bertrand, S Leonard.   

Abstract

The neuronal nicotinic acetylcholine receptors are excitatory ligand-gated channels. Widely expressed throughout the peripheral and central nervous system, their properties depend upon their subunit composition. Furthermore, genetic studies have revealed a high degree of variation at the genomic level and alternative splicing of the mRNAs coding for these integral membrane proteins. In particular, genes coding for alpha4 and alpha7 subunits harbour a high degree of polymorphisms. Although well characterised at their molecular and functional level, the role of these receptors in the central nervous system remains obscure. Despite accumulating evidence for the participation of nicotinic receptors in disorders of the central nervous system including nicotinic addiction, Parkinson's disease, Alzheimer's disease and Tourette's syndrome, the exact role of these receptors is still speculative. Because most of these phenotypes are complex and genetically heterogeneous, the investigation is difficult. However, in the past few years, significant progress has been made in understanding the contribution of nicotinic acetylcholine receptors to the origin of epilepsies and schizophrenia. By concentrating on the latest results gained for these diseases, we discuss in this review the possible relationships between neuronal nicotinic receptors and neurological and psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942031     DOI: 10.1016/s0166-4328(00)00199-6

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  18 in total

Review 1.  Autosomal dominant nocturnal frontal lobe epilepsy--a critical overview.

Authors:  Romina Combi; Leda Dalprà; Maria Luisa Tenchini; Luigi Ferini-Strambi
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

2.  Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-12       Impact factor: 11.205

Review 3.  Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update.

Authors:  Justin L Hoskin; Yazan Al-Hasan; Marwan Noel Sabbagh
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 4.  Nicotinic acetylcholine receptors: targets for commercially important insecticides.

Authors:  Neil S Millar; Ian Denholm
Journal:  Invert Neurosci       Date:  2007-01-10

Review 5.  The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.

Authors:  Melissa L Sinkus; Sharon Graw; Robert Freedman; Randal G Ross; Henry A Lester; Sherry Leonard
Journal:  Neuropharmacology       Date:  2015-02-19       Impact factor: 5.250

Review 6.  The apolipoprotein E gene, attention, and brain function.

Authors:  Raja Parasuraman; Pamela M Greenwood; Trey Sunderland
Journal:  Neuropsychology       Date:  2002-04       Impact factor: 3.295

7.  Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Jaskiran K Gill; Mari Savolainen; Gareth T Young; Ruud Zwart; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

Review 8.  Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders.

Authors:  Thomas W McAllister; Lanier Summerall
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

9.  Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.

Authors:  Monica E Calkins; William G Iacono; Deniz S Ones
Journal:  Brain Cogn       Date:  2008-10-18       Impact factor: 2.310

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.